| Rachel Hill May, ARNP | |
|
2901 Squalicum Pkwy, Bellingham, WA 98225-1851 | |
| (360) 734-5400 | |
| Not Available |
| Full Name | Rachel Hill May |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 2901 Squalicum Pkwy, Bellingham, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003391343 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | NP60883384 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bellingham, WA | Hospital |
| Peacehealth United General Medical Center | Sedro woolley, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Sound Inpatient Physicians Pllc | 5991618738 | 309 |
News Archive
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.
A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
› Verified 3 days ago
| Entity Name | South Sound Inpatient Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023285756 PECOS PAC ID: 5991618738 Enrollment ID: O20031107000668 |
News Archive
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.
A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
› Verified 3 days ago
| Entity Name | Cogent Healthcare Of Washington, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861430522 PECOS PAC ID: 2062306350 Enrollment ID: O20040209000839 |
News Archive
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.
A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
› Verified 3 days ago
| Entity Name | Sound Physicians Emergency Medicine Of Washington Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629532064 PECOS PAC ID: 7315279007 Enrollment ID: O20191030000855 |
News Archive
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.
A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Hill May, ARNP 137 S Forest St, Bellingham, WA 98225-5809 Ph: (360) 319-6727 | Rachel Hill May, ARNP 2901 Squalicum Pkwy, Bellingham, WA 98225-1851 Ph: (360) 734-5400 |
News Archive
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.
Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.
A new study by researchers at Monash University, Australia, has revealed that people who have been infected with COVID-19 showed sustained protection against reinfection for at least eight months.
A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
› Verified 3 days ago
Melanie R Hartley, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4545 Cordata Pkwy, Suite 1e, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5679 | |
Jody L Bauer, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3111 Woburn St Ste 201, Bellingham, WA 98226 Phone: 360-734-1420 Fax: 360-733-1659 | |
David Flarry, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2979 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-734-2700 | |
Amanda Vichas, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 302 36th St, Bellingham, WA 98225 Phone: 360-756-9793 Fax: 360-752-9007 | |
Graham Meeks, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2979 Squalicum Pkwy Ste 101, Bellingham, WA 98225 Phone: 360-734-2700 Fax: 360-734-8362 | |
Jaspreet S Khehra, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 220 Unity St, Bellingham, WA 98225 Phone: 360-676-6177 |